Oxiconazole (trade names Oxistat in the US, Oxizole in Canada) is an antifungal medication typically administered in a cream or lotion to treat skin infections, such as athlete's foot, jock itch and ringworm. It can also be prescribed to treat the skin rash. Chemically an imidazole derivative, oxiconazole inhibits fungal lanosterol 14-alpha-demethylase (CYP51), blocking ergosterol biosynthesis and causing disruption of fungal cell membrane structure and function. The compound displays potent in vitro activity against common dermatophytes and some Candida species and is formulated for topical delivery to achieve high local concentrations with minimal systemic exposure. Typical topical formulations use a 1 percent strength in an oil-in-water cream or lotion base optimized for skin penetration; pharmacokinetic data show low systemic absorption after dermal application. Common adverse effects are local and include mild irritation or contact dermatitis; systemic effects are rare with recommended topical use.
Parent: Oxiconazole
Parent: Oxiconazole
Parent: Oxiconazole / Miconazole
Parent: Oxiconazole
Parent: Oxiconazole
Typical analytical specifications for oxiconazole API and finished topical products follow high performance liquid chromatography methods with an assay specification commonly around 98.0 to 102.0 percent of labeled amount. Related substances and impurities observed in manufacturing and stability studies include potential dealkylation products, N-oxide formation, oxidative hydroxylation products and dechlorinated analogues. Typical internal quality limits used by manufacturers are individual unspecified impurities not greater than 0.2 percent and total impurities not greater than 1.0 percent, with specific identified related compounds often held to limits of 0.05 to 0.5 percent depending on toxicological qualification and regulatory expectations. Identification and qualification thresholds follow ICH principles, and stability and batch release testing use validated HPLC methods to quantify and characterize each impurity.
Oxiconazole is used topically to treat superficial fungal infections of the skin, notably tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm), and it may be prescribed for certain yeast-related dermatoses based on clinical judgement.
“Better” depends on organism susceptibility, formulation, and clinical context. Oxiconazole tends to show greater in vitro potency against many dermatophytes compared with clotrimazole, but clotrimazole has a long track record, broad availability and multiple formulation options. Choice is guided by diagnosis, local resistance patterns, tolerability and clinician preference.
They are different agents with overlapping activity. Oxiconazole is formulated for topical dermatologic use and often has strong activity against dermatophytes. Ketoconazole exists as topical and oral formulations; systemic ketoconazole has important safety considerations that limit its use. For topical skin infections, comparative effectiveness can vary by pathogen and formulation; treatment selection should consider efficacy, safety and regulatory guidance.
Treatment duration depends on the infection and clinical response. Typical topical courses range from two to four weeks; some infections may require longer treatment until lesions and scaling resolve and clinicians confirm mycological cure. Follow the prescribing information or your healthcare provider’s instructions and complete the full recommended course even if symptoms improve earlier.
